Tracking predictions from the podcast Oh No, Ross and Carrie! episode 399. Transcript available at https://maximumfun.org/transcripts/oh-no-ross-and-carrie/transcript-oh-no-ross-and-carrie-ep-399-ross-carrie-and-psychics-predict-2024-cancer-cures-and-election-edition/
Carrie Poppy: I hope he’s right too. “Then there were also many advances in the medical field and care. Advances in Alzheimer’s as well.”
Ross Blocher: Interesting. I feel like I saw the same prediction from someone else. Okay.
Carrie Poppy: Yeah. “Advances” is so nonspecific, but we’ll work with it.
I will resolve according to their evaluation in 2025 ("No" for a zero on their scale, "N/A" for one, and "Yes" for two)
With the podcast ending, I can no longer simply defer to the host's judgements for the resolution. Please vote in this poll if you have thoughts on how I should resolve these markets:
1,000🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ6 |
Perpelxity says YES, and I recall a bunch of controversy around Alzheimer's drugs so that's good enough for me.
Yes, 2024 saw significant advances in Alzheimer's disease research and treatment. Several key developments include:
1. New drug approvals: The first disease-modifying treatments for Alzheimer's, donanemab and lecanemab, were approved for use in the UK[2]. Additionally, TauRX applied for approval of their drug hydromethylthionine mesylate (HMTM) for treating mild cognitive impairment or mild to moderate Alzheimer's-related dementia[2].
2. Clinical trials: There were 171 ongoing studies and 134 drugs being tested in clinical trials, with 77% of new treatments potentially disease-modifying[1]. Over 51,000 people participated in Alzheimer's disease clinical trials worldwide[3].
3. Blood biomarker research: Significant progress was made in developing blood tests for Alzheimer's diagnosis, with some tests showing up to 90% accuracy in identifying the disease[5].
4. Focused ultrasound breakthrough: Clinical trial results showed that focused ultrasound-induced blood-brain barrier opening with drug delivery may help clear amyloid-beta plaques in Alzheimer's patients[4].
5. Risk factor identification: Researchers identified two new risk factors for dementia: untreated vision loss and high cholesterol[2].
These advancements represent substantial progress in understanding, diagnosing, and treating Alzheimer's disease, making 2024 a landmark year for Alzheimer's research.
Citations:
[2] https://www.alzheimers.org.uk/blog/2024-looking-back-exciting-year-research-alzheimers-society
[5] https://aaic.alz.org/releases-2024/highlights-aaic-2024.asp
[6] https://www.nia.nih.gov/about/2024-nih-dementia-research-progress-report
[7] https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14325
@traders my resolution criteria for this market failed to account for the possibility that we wouldn't get ratings from Ross and Carrie, but with the podcast having ended that now seems pretty likely. Please vote in this poll to let me know if you'd prefer me to use my judgement instead, or just resolve this market N/A.
Either way, I will not trade in this market.